التفاصيل البيبلوغرافية
| العنوان: |
Interleukin-2-based therapies in cancer. |
| المؤلفون: |
Raeber ME; Department of Immunology, University Hospital Zurich, Zurich, Switzerland., Sahin D; Department of Immunology, University Hospital Zurich, Zurich, Switzerland., Boyman O; Department of Immunology, University Hospital Zurich, Zurich, Switzerland.; Faculty of Medicine and Faculty of Science, University of Zurich, Zurich, Switzerland. |
| المصدر: |
Science translational medicine [Sci Transl Med] 2022 Nov 09; Vol. 14 (670), pp. eabo5409. Date of Electronic Publication: 2022 Nov 09. |
| نوع المنشور: |
Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: Washington, DC : American Association for the Advancement of Science |
| مواضيع طبية MeSH: |
Interleukin-2*/therapeutic use , Neoplasms*/drug therapy, Humans ; Immunotherapy/methods |
| مستخلص: |
Molecular insights into the mechanism of beneficial and adverse effects of interleukin-2 (IL-2) have resulted in the development of improved IL-2 formulations with IL-2 receptor bias and tissue-targeting properties. Several of these compounds are currently in clinical development and are ushering IL-2 therapy into the current era of cancer immunotherapy. |
| المشرفين على المادة: |
0 (Interleukin-2) |
| تواريخ الأحداث: |
Date Created: 20221109 Date Completed: 20221111 Latest Revision: 20221216 |
| رمز التحديث: |
20221217 |
| DOI: |
10.1126/scitranslmed.abo5409 |
| PMID: |
36350987 |
| قاعدة البيانات: |
MEDLINE |
